Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothea Weckermann

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
European Urology|January 30, 2007
Editorial comment on: Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imagingDorothea Weckermann
MMW Fortschritte Der Medizin|November 11, 2011
[Emergency checklist: Priapism]Dorothea Weckermann
European Urology|June 15, 2014
Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetesDorothea Weckermann
European Urology|May 30, 2012
Words of wisdom. Re: Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotypeDorothea Weckermann
Urologie (Heidelberg, Germany)|October 10, 2022
[Gender aspects in urology]Jennifer Kranz, Dorothea Weckermann
European Urology|August 13, 2004
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analoguesDorothea Weckermann, Rolf Harzmann
Urologie (Heidelberg, Germany)|August 18, 2022
[Gender-associated differences in bladder cancer]Georgios Gakis, Dorothea Weckermann
European Urology|December 8, 2004
Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?Dorothea Weckermann, Friedhelm Wawroschek, Rolf Harzmann
Onkologie|June 4, 2005
Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemmaEckart Gronau, Marcus Goppelt, Rolf Harzmann, et al.
BJU International|May 12, 2006
Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomyDorothea Weckermann, Marcus Goppelt, Robert Dorn, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
European Urology|January 30, 2007
Editorial comment on: Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imagingDorothea Weckermann
MMW Fortschritte Der Medizin|November 11, 2011
[Emergency checklist: Priapism]Dorothea Weckermann
European Urology|June 15, 2014
Re: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetesDorothea Weckermann
European Urology|May 30, 2012
Words of wisdom. Re: Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotypeDorothea Weckermann
Urologie (Heidelberg, Germany)|October 10, 2022
[Gender aspects in urology]Jennifer Kranz, Dorothea Weckermann
European Urology|August 13, 2004
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analoguesDorothea Weckermann, Rolf Harzmann
Urologie (Heidelberg, Germany)|August 18, 2022
[Gender-associated differences in bladder cancer]Georgios Gakis, Dorothea Weckermann
European Urology|December 8, 2004
Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?Dorothea Weckermann, Friedhelm Wawroschek, Rolf Harzmann
Onkologie|June 4, 2005
Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemmaEckart Gronau, Marcus Goppelt, Rolf Harzmann, et al.
BJU International|May 12, 2006
Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomyDorothea Weckermann, Marcus Goppelt, Robert Dorn, et al.
Pageof 4